乌鸦传媒

Ian Ingram

Ian Ingram

Authors >

Ian Ingram

Ian Ingram joined 乌鸦传媒 in 2018 as Deputy Managing Editor, and covers oncology for the site. Ian Ingram has been a medical editor for the past decade. Prior to joining 乌鸦传媒, he was managing editor of Cancer Network, directing the website鈥檚 news coverage and video production. Ian has also worked as a fact-checker, was an assistant editor at Narrative Magazine, and a manuscript reader at the Paris Review. He holds a B.A. in journalism from Purchase College. Ian lives in Connecticut, enjoys tennis, and almost always bowls a perfect game.

Connect:

email image

Latest from Ian Ingram

GuCS over a computer rendering of the genitourinary system

<乌鸦传媒>Radionuclide Tx Wins in Third-Line Metastatic CRPC

Early trial shows improved PFS, response rates versus cabazitaxel

Vials of Rituxan (rituximab) and Gazyva (obinutuzumab)

<乌鸦传媒>Anti-CD20 Drugs Tied to Severe COVID in Cancer Patients

Plus: Active chemo treatment may not be a COVID risk factor

WCLC over a computer rendering of a person receiving stereotactic body radiation for lung cancer

<乌鸦传媒>KRAS Inhibitor Continues to Impress in NSCLC

Sotorasib yielded deep and durable responses in over one-third of patients

A close up of a Black woman with a pink breast cancer ribbon pinned to her tank top

<乌鸦传媒>Oncotype DX Misses on Breast Cancer Risk in Black Women

Accuracy of 21-gene recurrence score worse compared with white women

A box of Tagrisso (osimertinib) tablets and a vial of Avastin (bevacizumab)

<乌鸦传媒>Targeted Combo Fails in EGFR-Mutant NSCLC

Osimertinib-bevacizumab no better than osimertinib alone

SABCS over a photo of women holding pink breast cancer ribbons

<乌鸦传媒>Doctor-Patient Discord in Reporting Radiation Toxicity

Physicians underrecognized substantial symptoms in more than half of patients

SABCS over a photo of women holding pink breast cancer ribbons

<乌鸦传媒>Adjuvant Palbociclib Fails in Early, High-Risk Breast Cancer

No iDFS benefit with 1 year of CDK4/6 inhibition following neoadjuvant chemotherapy

ASH over a computer rendering of blood flowing through an artery

<乌鸦传媒>Chemo-Free Combo Boosts PFS in First-Line CLL

PI3K-delta-based regimen also topped chemoimmunotherapy in relapsed setting

ASH over a computer rendering of blood flowing through an artery

<乌鸦传媒>Fixed-Duration Ibrutinib-Venetoclax Promising in First-Line CLL

DFS at 1 year reaches 95% in patients with undetectable MRD

ASH over a computer rendering of blood flowing through an artery

<乌鸦传媒>JAK Inhibitor Wins in Second-Line Chronic GVHD

Twice as many patients achieved a response at week 24

鈥�

22